The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•29 April 2026•

1 min read

Sangamo Therapeutics to Move Listing from Nasdaq to OTCQB Venture Market

Key Facts

1Sangamo Therapeutics announced its common stock will transition from The Nasdaq Capital Market to the OTCQB Venture Market.

2The transition to the new trading market is scheduled to occur on Tuesday, May 5, 2026.

Sangamo Therapeutics has announced that its common stock will transition its listing from The Nasdaq Capital Market to the OTCQB Venture Market. The transition is scheduled to take effect at the opening of business on Tuesday, May 5, 2026. This move typically occurs when a company can no longer meet the stringent continued listing requirements of a major exchange like Nasdaq. Trading on the OTCQB market often results in reduced liquidity and lower trading volumes compared to primary exchanges. Furthermore, such a transition can impact investor confidence and limit institutional participation in the stock. Market analysts view this delisting as a significant shift in the company's regulatory and financial standing within the genomic medicine sector.